American College of Rheumatology core set components at baseline, week 4 and week 24 (last observation carried forward) in TNF antagonist-IR and DMARD-IR subgroups of patients
| Baseline | Week 4 | Week 24 | ||||
|---|---|---|---|---|---|---|
| Component | TNF antagonist-IR | DMARD-IR | TNF antagonist-IR | DMARD-IR | TNF antagonist-IR | DMARD-IR |
| SJC/28 (n) | 12.3±8.4 | 13.3±7.3 | 6.6±5.9 | 6.2±7.1 | 3.8±4.9 | 3.0±4.9 |
| TJC/28 (n) | 20.7±14.2 | 20.0±11.2 | 13.1±13.1 | 10.3±11.4 | 8.7±11.7 | 5.3±8.4 |
| CRP (mg/l) | 26.7±28.6 | 20.7±32.2 | 7.1±17.2 | 4.5±12.8 | 2.7±4.3 | 3.3±9.5 |
| ESR (mm/h) | 40.5±24.4 | 35.6±20.3 | 11.7±14.8 | 9.3±12.5 | 7.2±10.1 | 6.9±9.1 |
| VAS physician disease activity (mm) | 64.6±16.6 | 61.2±19.4 | 38.1±23.8 | 27.9±20.2 | 23.9±23.2 | 13.2±14.9 |
| VAS patient pain (mm) | 67.0±18.0 | 60.4±21.5 | 44.6±27.1 | 36.0±26.7 | 30.6±24.8 | 23.6±26.3 |
| HAQ-DI | 1.67±0.62 | 1.33±0.65 | 1.33±0.64 | 1.01±0.69 | 1.20±0.72 | 0.84±0.74 |
Data shown as mean±SD.
While there was no difference between patients pretreated with one or two TNF antagonists, patients with three TNF antagonists in the history showed a lesser response which, due to low numbers, was not statistically significant (data not shown)
CRP, C reactive protein; DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disease Index; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; TNF antagonist-IR, inadequate response to TNF antagonists; VAS, visual analogue scale.